Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1494)	4/16/2004 12:06:41 PM
From: Biomaven	Read Replies (1) \| Respond to of 1826

MGI Pharma's Aloxi Drug Sales Seen Strong 04.16.04, 11:11 AM ET Banc of America said it upgraded MGI Pharma (nasdaq: MOGN - news - people ) to a "buy" from a "neutral" rating, citing robust demand for Aloxi, the company's anti-nausea treatment for chemotherapy patients. The research firm also raised its 12-month price target for the stock to $74 from $63. According to a Banc of America survey of 21 oncologists, Aloxi, which was launched in September, is generating higher sales than the market had expected. Based on the physicians' responses, the research firm calculated that Aloxi is poised to gain approximately a 38% market share, which contrasts favorably with Banc of America's previous market share estimate of 25%. The research house calculated that Aloxi's peak annual sales could exceed $500 million, up from a prior Banc of America estimate of $300 million to $400 million. Banc of America said: "MGI Pharma is still expensive, but our bias to lighten positions on price spikes is now changed to buying on dips based on the longer-term potential for Aloxi." Elsewhere in the specialty pharmaceuticals sector, Banc of America said its two "top picks" are Alcon (nyse: ACL - news - people ) and Teva Pharmaceutical Industries (nasdaq: TEVA - news - people ), both of which are rated "buy" and carry price targets of $72. The research firm's "least favorite" stocks in the group are Biovail (nyse: BVF - news - people ) and Bausch & Lomb (nyse: BOL - news - people ), which carry "sell" ratings and have respective price targets of $15 and $43.

To: Icebrg who wrote (1494)	5/18/2004 4:33:00 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma "market outperform" Tuesday, May 18, 2004 1:07:25 PM ET JMP Securities NEW YORK, May 18 (New Ratings) - Analyst Howard Liang of JMP Securities maintains his "market outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $75. In a research note published this morning, the analyst mentions that the April sales of the company's Aloxi drug are likely to have exceeded expectations. MGI Pharma's Aloxi drug, which is in the early stage of market penetration, is expected to offer substantial earnings growth opportunities in the forthcoming quarters, the analysts say. The company is likely to pursue acquisitions in the near term to boost its product portfolio, JMP Securities adds.